third-line therapy

third-line therapy

Any alternative to conventional–surgery, chemotherapy or RT for malignancy. Cf Unproven forms of cancer therapy.
References in periodicals archive ?
This is the second POC Phase II study for fruquintinib aimed at comparing the efficacy and safety of fruquintinib plus best supportive care ("BSC") versus placebo plus BSC in patients with NSCLC as a third-line therapy.
To our knowledge, this is the first multicentre survey to investigate the effectiveness of targeted therapies related to bone metastases in patients who received third-line therapy for mRCC.
A new therapy that delivers effective treatment with manageable side effects offers real hope for these patients that fail second- or third-line therapy.
Because of these side effects, anti-TNF antibodies are most often used only as a second- or third-line therapy, despite evidence that earlier use could improve patient outcomes.
At an FDA advisory panel meeting in September on the drug, the panel urged that it be used only as a third-line therapy.
Earlier PTSD treatment guidelines still in place--including the 2007 Australian guidelines, the 2005 British Association for Psychopharmacology guidelines, and the Canadian treatment guidelines--list mirtazapine as third-line therapy to be reserved for seriously treatment-resistant cases.
London, March 11 (ANI): Two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients, according to a new study.
Although cetuximab is used more commonly in second- and third-line therapy where treatment duration is shorter, KRAS-based treatment selection is likely to result in cost savings across all lines of therapy.
However, the increased emphasis on asthma as a disease of inflammation leading to bronchial hyperresponsiveness has shifted the use of inhaled aerosol steroids from second-line or third-line therapy to first-line, primary therapy.
Trastuzumab (Herceptin), a targeted monoclonal antibody, was initially approved in 1998 for use in HER2-positive metastatic breast cancer as a first line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy.
6% of patients received some form of third-line therapy, including chemotherapy, immunotherapy and other treatments, versus 61.
If the response is sustained, a lopinavir containing combination holds great promise as third-line therapy.

Full browser ?